Developer docs
API playgroundTry for free, no card

Search company profiles

Nuventra

Full company profile

uuid000l8u5

Namestring
Nuventra
Websiteurl
nuventra.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Nuventra is a drug development consulting firm founded in 2008 and headquartered in Cary, North Carolina, with an employee base of 51-100. The company provides specialized clinical pharmacology and drug development consulting services, and the available data indicates it operates within the broader Allucent platform — a global full-service contract research organization (CRO) serving small and mid-sized biotech and biopharma companies. Its services span the entire drug development lifecycle, from early-stage discovery through clinical development and post-marketing approval, with core competencies in pharmacokinetics, modeling and simulation, and regulatory strategy.

The platform's technical and service surface includes clinical development (study start-up, the IGNITE clinical research site network, patient recruitment and retention, decentralized clinical trials, data management, biostatistics, and medical monitoring), clinical pharmacology (drug development strategy, modeling and simulation, end-to-end pharmacokinetics, and embedded pharmacologist support), regulatory strategy (CMC/preclinical, clinical strategy, regulatory submissions, and GxP consulting), and drug safety/pharmacovigilance. Therapeutic specialization is organized around centers of expertise in oncology and hematology, neuroscience, infectious disease and vaccines, immunology and inflammation, cardiometabolic disease, rare diseases, and cell and gene therapy.

The business model is professional-services based: revenue is generated through contract research and consulting engagements priced per project rather than via publicly disclosed rates. Go-to-market is an enterprise/field consultative sales motion using "Schedule a Consultation" and "Request a Proposal" engagement paths, supported by content marketing (blogs, white papers, case studies), webinars, podcasts, industry events, and organic social. The primary customer base is small and mid-sized biotech companies that lack internal resources for complex, multi-region clinical development and require specialized therapeutic and regulatory expertise.

Short descriptiontext

Nuventra is a drug development consulting firm providing clinical pharmacology, pharmacokinetics, and regulatory strategy services, operating within the Allucent full-service CRO platform that serves small and mid-sized biotech companies across the drug development lifecycle.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug development consulting, clinical pharmacology services, pharmacokinetics consulting, regulatory strategy services, pharmaceutical CRO services
Industry2 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Other Scientific and Technical Consulting Services54169
  • Other Scientific and Technical Consulting Services541690
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Pharmaceutical Consulting Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Allucent provides contract research organization (CRO) services to biotech and biopharma companies, offering clinical development, clinical pharmacology, regulatory strategy, and drug safety services. Revenue is generated through service contracts for clinical trials and consulting engagements across all phases of drug development.

allucent.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nuventra offers drug development consulting services for pharmaceutical and biotechnology clients, spanning clinical pharmacology, pharmacokinetics, regulatory strategy, clinical development, drug safety/pharmacovigilance, and government/public-health programs. The firm combines scientific consulting with clinical operations (including decentralized clinical trial capabilities and a proprietary investigator/site network) to guide assets from preclinical planning through regulatory submission and post-marketing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 105+ successful marketing applications and approved products
+4 more records
Product and service1 record
1Clinical Development Services
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Simulations Plus provides modeling-and-simulation software and services for PK/PD, physiologically-based pharmacokinetics, and quantitative systems pharmacology — closely overlapping with the clinical pharmacology consulting core of Nuventra.

TypeBroad incumbent
Description

Syneos Health is a large CRO with end-to-end clinical development and clinical pharmacology services competing for biotech Phase I-III work that overlaps Nuventra's target engagements.

TypeBroad incumbent
Description

IQVIA is the largest global CRO and clinical pharmacology provider with extensive biosimulation and regulatory capabilities — represents the scaled incumbent end of the spectrum Nuventra competes within for biotech clinical development work.

TypeDirect peer
Description

Certara is a leading biosimulation and clinical pharmacology services/software firm providing PK/PD modeling, regulatory science, and drug development consulting — a near-direct analog to Nuventra's clinical-pharmacology focus, scaled larger and publicly traded.

TypeBroad incumbent
Description

Charles River provides preclinical through clinical drug development services including safety, pharmacology, and regulatory consulting — an adjacent competitor in the drug-development consulting space serving similar biotech clients.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO with strong scientific and clinical-pharmacology depth targeting small and mid-sized biotech — closely comparable size, customer profile, and therapeutic mix to Nuventra.

TypeBroad incumbent
Description

ICON is a top-three global CRO with deep biotech focus post-PRA Health Sciences acquisition, offering end-to-end clinical development and clinical pharmacology services overlapping Nuventra's value proposition.

TypeBroad incumbent
Description

PPD (now part of Thermo Fisher Scientific) is a global CRO offering clinical pharmacology, modeling-and-simulation, and biotech-focused drug development services — a scaled incumbent competitor for the same customer segment.

TypeBroad incumbent
Description

Allucent is the broader full-service CRO whose service portfolio (clinical pharmacology, clinical development, regulatory strategy) encompasses Nuventra's niche; the firmographics and dataset strongly suggest Nuventra operates within or alongside Allucent.

TypeBroad incumbent
Description

Medpace is a mid-to-large full-service CRO with strong scientific/medical credibility serving small and mid-sized biotechs — directly comparable customer base and increasingly overlapping clinical-pharmacology capabilities to Nuventra.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment9 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuventra

Pharmaceutical Consulting Servicesnuventra.com

Nuventra is a drug development consulting firm providing clinical pharmacology, pharmacokinetics, and regulatory strategy services, operating within the Allucent full-service CRO platform that serves small and mid-sized biotech companies across the drug development lifecycle.

What Nuventra does

Nuventra is a drug development consulting firm founded in 2008 and headquartered in Cary, North Carolina, with an employee base of 51-100. The company provides specialized clinical pharmacology and drug development consulting services, and the available data indicates it operates within the broader Allucent platform — a global full-service contract research organization (CRO) serving small and mid-sized biotech and biopharma companies. Its services span the entire drug development lifecycle, from early-stage discovery through clinical development and post-marketing approval, with core competencies in pharmacokinetics, modeling and simulation, and regulatory strategy.

The platform's technical and service surface includes clinical development (study start-up, the IGNITE clinical research site network, patient recruitment and retention, decentralized clinical trials, data management, biostatistics, and medical monitoring), clinical pharmacology (drug development strategy, modeling and simulation, end-to-end pharmacokinetics, and embedded pharmacologist support), regulatory strategy (CMC/preclinical, clinical strategy, regulatory submissions, and GxP consulting), and drug safety/pharmacovigilance. Therapeutic specialization is organized around centers of expertise in oncology and hematology, neuroscience, infectious disease and vaccines, immunology and inflammation, cardiometabolic disease, rare diseases, and cell and gene therapy.

The business model is professional-services based: revenue is generated through contract research and consulting engagements priced per project rather than via publicly disclosed rates. Go-to-market is an enterprise/field consultative sales motion using "Schedule a Consultation" and "Request a Proposal" engagement paths, supported by content marketing (blogs, white papers, case studies), webinars, podcasts, industry events, and organic social. The primary customer base is small and mid-sized biotech companies that lack internal resources for complex, multi-region clinical development and require specialized therapeutic and regulatory expertise.

Nuventra firmographics

Firmographics
Name
Nuventra
Website
https://nuventra.com
Company type
Private
Founded year
2008
Headcount range
1–10 employees
Short description
Nuventra is a drug development consulting firm providing clinical pharmacology, pharmacokinetics, and regulatory strategy services, operating within the Allucent full-service CRO platform that serves small and mid-sized biotech companies across the drug development lifecycle.
Ownership category
akta.pro rank

Nuventra industry classification

Industry
Product category
Pharmaceutical Consulting Services
NAICS
Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug development consulting
  • Clinical pharmacology services
  • Pharmacokinetics consulting
  • Regulatory strategy services
  • Pharmaceutical CRO services

Where Nuventra is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Nuventra business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Contract Research Services: Allucent provides contract research organization (CRO) services to biotech and biopharma companies, offering clinical development, clinical pharmacology, regulatory strategy, and drug safety services. Revenue is generated through service contracts for clinical trials and consulting engagements across all phases of drug development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Nuventra product offering

Product offering

Core offering

Nuventra offers drug development consulting services for pharmaceutical and biotechnology clients, spanning clinical pharmacology, pharmacokinetics, regulatory strategy, clinical development, drug safety/pharmacovigilance, and government/public-health programs. The firm combines scientific consulting with clinical operations (including decentralized clinical trial capabilities and a proprietary investigator/site network) to guide assets from preclinical planning through regulatory submission and post-marketing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Development Services

Quantifiable outcome

  • 105+ successful marketing applications and approved products
  • +4 more outcomes

Companies that use Nuventra

Customer profile

Segments9 records

Ideal customer profiles2 records

Nuventra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Nuventra partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves4 records

Expansion highlights5 records

Nuventra competitors and assessment

Company assessment

Direct peers

  • Simulations Plus: Simulations Plus provides modeling-and-simulation software and services for PK/PD, physiologically-based pharmacokinetics, and quantitative systems pharmacology — closely overlapping with the clinical pharmacology consulting core of Nuventra.
  • Certara: Certara is a leading biosimulation and clinical pharmacology services/software firm providing PK/PD modeling, regulatory science, and drug development consulting — a near-direct analog to Nuventra's clinical-pharmacology focus, scaled larger and publicly traded.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with strong scientific and clinical-pharmacology depth targeting small and mid-sized biotech — closely comparable size, customer profile, and therapeutic mix to Nuventra.

Broad incumbents

  • Syneos Health: Syneos Health is a large CRO with end-to-end clinical development and clinical pharmacology services competing for biotech Phase I-III work that overlaps Nuventra's target engagements.
  • IQVIA: IQVIA is the largest global CRO and clinical pharmacology provider with extensive biosimulation and regulatory capabilities — represents the scaled incumbent end of the spectrum Nuventra competes within for biotech clinical development work.
  • Charles River Laboratories: Charles River provides preclinical through clinical drug development services including safety, pharmacology, and regulatory consulting — an adjacent competitor in the drug-development consulting space serving similar biotech clients.
  • ICON plc: ICON is a top-three global CRO with deep biotech focus post-PRA Health Sciences acquisition, offering end-to-end clinical development and clinical pharmacology services overlapping Nuventra's value proposition.
  • Pharmaceutical Product Development (PPD): PPD (now part of Thermo Fisher Scientific) is a global CRO offering clinical pharmacology, modeling-and-simulation, and biotech-focused drug development services — a scaled incumbent competitor for the same customer segment.
  • Allucent: Allucent is the broader full-service CRO whose service portfolio (clinical pharmacology, clinical development, regulatory strategy) encompasses Nuventra's niche; the firmographics and dataset strongly suggest Nuventra operates within or alongside Allucent.
  • Medpace: Medpace is a mid-to-large full-service CRO with strong scientific/medical credibility serving small and mid-sized biotechs — directly comparable customer base and increasingly overlapping clinical-pharmacology capabilities to Nuventra.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights4 records

Customer concentration

Nuventra social profiles

Digital presence

Nuventra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuventra leadership team

Management profile

Number of profiles

Profiles2 records

Nuventra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuventra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuventra

What does Nuventra do?

Nuventra offers drug development consulting services for pharmaceutical and biotechnology clients, spanning clinical pharmacology, pharmacokinetics, regulatory strategy, clinical development, drug safety/pharmacovigilance, and government/public-health programs. The firm combines scientific consulting with clinical operations (including decentralized clinical trial capabilities and a proprietary investigator/site network) to guide assets from preclinical planning through regulatory submission and post-marketing.

When was Nuventra founded?

Nuventra was founded in 2008. It employs 1 to 10 people.

Where is Nuventra based?

Nuventra is headquartered in Cary, United States, in the North America region.

How does Nuventra make money?

One revenue line is on record: contract Research Services.

Who are Nuventra's main competitors?

Direct peers on record are Simulations Plus, Certara and Worldwide Clinical Trials. Broad incumbents are Syneos Health, IQVIA, Charles River Laboratories, ICON plc, Pharmaceutical Product Development (PPD), Allucent and Medpace.

Does Nuventra have an API?

No public API is recorded for Nuventra.

What industry is Nuventra in?

Nuventra's product category is Pharmaceutical Consulting Services. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCATO SMS Acquires Nuventra To Expand Drug Development Offering Into Clinical PharmacologyCATO SMS, a global provider of regulatory and clinical research services, has acquired Nuventra, Inc. to expand its offering into clinical pharmacology. Headquartered in Durham, N.C., Nuventra is a leading clinical pharmacology science and services provider with expertise in pharmacokinetics, pharmacodynamics, pharmacometrics, and biosimulation, serving more than 650 biopharmaceutical companies. The acquisition adds specialized scientific capabilities to CATO SMS's portfolio, marking the company's third business acquisition in two years as it expands its oncology, regulatory, and clinical pharmacology solutions.NewswireNuventra Pharma Sciences Appoints Daniel Roy, M.H.A, as PresidentNuventra Pharma Sciences appointed Daniel Roy as president, effective January 5, 2021. Roy previously served as vice president of corporate strategy and business development, with 16 years of experience. CEO Geoffrey Banks will remain in his role.PR NewswireNuventra Pharma Sciences Appoints Daniel Roy, M.H.A, as PresidentNuventra Pharma Sciences announced the appointment of Daniel Roy as President, effective immediately. Roy joined the company in 2014 and has steadily advanced through roles including Manager of Marketing, Senior Director of Business Development, and most recently Vice President of Corporate Strategy and Business Development. CEO Geoffrey Banks commented that Roy's business acumen and pharma industry knowledge will be integral to Nuventra's continued growth as a leader in clinical pharmacology science and services.